CA2794389C - Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers - Google Patents

Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers Download PDF

Info

Publication number
CA2794389C
CA2794389C CA2794389A CA2794389A CA2794389C CA 2794389 C CA2794389 C CA 2794389C CA 2794389 A CA2794389 A CA 2794389A CA 2794389 A CA2794389 A CA 2794389A CA 2794389 C CA2794389 C CA 2794389C
Authority
CA
Canada
Prior art keywords
salt
water
methanesulfonate
ralfinamide
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2794389A
Other languages
English (en)
French (fr)
Other versions
CA2794389A1 (en
Inventor
Claudio Giordano
Erwin Waldvogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newron Pharmaceuticals SpA
Original Assignee
Newron Pharmaceuticals SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2794389(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharmaceuticals SpA filed Critical Newron Pharmaceuticals SpA
Publication of CA2794389A1 publication Critical patent/CA2794389A1/en
Application granted granted Critical
Publication of CA2794389C publication Critical patent/CA2794389C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2794389A 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers Active CA2794389C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10161207 2010-04-27
EP10161207.5 2010-04-27
PCT/EP2011/055309 WO2011134763A1 (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers

Publications (2)

Publication Number Publication Date
CA2794389A1 CA2794389A1 (en) 2011-11-03
CA2794389C true CA2794389C (en) 2016-08-23

Family

ID=42634917

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2794389A Active CA2794389C (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers

Country Status (27)

Country Link
US (2) US9505708B2 (enExample)
EP (1) EP2563355B1 (enExample)
JP (3) JP5808392B2 (enExample)
KR (1) KR101851118B1 (enExample)
CN (2) CN105037188B (enExample)
AR (1) AR085171A1 (enExample)
AU (1) AU2011246707B2 (enExample)
BR (1) BR112012027623B1 (enExample)
CA (1) CA2794389C (enExample)
CY (1) CY1117879T1 (enExample)
DK (1) DK2563355T3 (enExample)
EA (1) EA021389B1 (enExample)
ES (1) ES2590128T3 (enExample)
HR (1) HRP20161077T1 (enExample)
HU (1) HUE030504T2 (enExample)
IL (1) IL222532A (enExample)
LT (1) LT2563355T (enExample)
ME (1) ME02509B (enExample)
MX (1) MX342697B (enExample)
NZ (2) NZ602648A (enExample)
PL (1) PL2563355T3 (enExample)
PT (1) PT2563355T (enExample)
RS (1) RS55084B1 (enExample)
SI (1) SI2563355T1 (enExample)
SM (1) SMT201600266B (enExample)
TW (1) TWI492919B (enExample)
WO (1) WO2011134763A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2563355T3 (pl) * 2010-04-27 2016-12-30 Sposób wytwarzania soli stanowiących metanosulfoniany ralfinamidu lub jego enancjomerów R
CN103804341B (zh) * 2012-11-13 2018-04-10 中国人民解放军军事医学科学院毒物药物研究所 酰胺衍生物及其医药用途
CN104761531B (zh) * 2014-01-03 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 镇痛活性化合物及其医药用途
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
CN115368310B (zh) * 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
DE60209152T2 (de) 2001-09-03 2006-08-03 Newron Pharmaceuticals S.P.A. Pharmazeutische zusammensetzung, umfassend gabapentin oder ein analogon davon und ein alpha-aminoamid
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2005018627A1 (en) 2003-08-25 2005-03-03 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
RU2391973C2 (ru) * 2004-09-10 2010-06-20 Ньюрон Фармасьютикалс С.П.А. Применение (галобензилокси)бензиламино-пропанамидов для производства лекарственных средств, действующих как селективные модуляторы натриевых и/или кальциевых каналов
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RS55464B1 (sr) * 2006-06-19 2017-04-28 Newron Pharm Spa 2-[4-(3- i 2 fluorbenziloksi) benzilamino] propanamidi visokog stepena čistoće za upotrebu kao lekovi i farmaceutski preparati koji ih sadrže
JP5315674B2 (ja) * 2007-11-19 2013-10-16 セントラル硝子株式会社 非水電池用電解液及びこれを用いた非水電池
JP5460613B2 (ja) * 2007-12-11 2014-04-02 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 高純度を有する２−［４−（３−または２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法
KR101500962B1 (ko) 2007-12-19 2015-03-10 뉴론 파마슈티칼즈 에스. 피. 에이. 정신 장애의 치료에 유용한 알파­아미노아미드 유도체
WO2009109334A1 (en) 2008-03-07 2009-09-11 Newron Pharmaceuticals S.P.A. (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
PL2563355T3 (pl) * 2010-04-27 2016-12-30 Sposób wytwarzania soli stanowiących metanosulfoniany ralfinamidu lub jego enancjomerów R

Also Published As

Publication number Publication date
US9856207B2 (en) 2018-01-02
US20170029365A1 (en) 2017-02-02
CN105037188B (zh) 2017-06-23
US9505708B2 (en) 2016-11-29
CN102858330A (zh) 2013-01-02
TW201139344A (en) 2011-11-16
EA201291116A1 (ru) 2013-04-30
JP6450420B2 (ja) 2019-01-09
JP2015180664A (ja) 2015-10-15
CY1117879T1 (el) 2017-05-17
EP2563355B1 (en) 2016-06-08
AU2011246707B2 (en) 2014-11-20
TWI492919B (zh) 2015-07-21
PL2563355T3 (pl) 2016-12-30
MX2012012093A (es) 2012-12-17
AR085171A1 (es) 2013-09-18
CN105037188A (zh) 2015-11-11
EA021389B1 (ru) 2015-06-30
NZ700221A (en) 2016-04-29
JP6345154B2 (ja) 2018-06-20
SI2563355T1 (sl) 2016-10-28
WO2011134763A1 (en) 2011-11-03
SMT201600266B (it) 2016-08-31
CN102858330B (zh) 2015-07-22
HRP20161077T1 (hr) 2016-10-21
JP2017197553A (ja) 2017-11-02
CA2794389A1 (en) 2011-11-03
ME02509B (me) 2017-02-20
US20130039983A1 (en) 2013-02-14
ES2590128T3 (es) 2016-11-18
DK2563355T3 (en) 2016-09-12
BR112012027623B1 (pt) 2021-07-06
JP5808392B2 (ja) 2015-11-10
IL222532A0 (en) 2012-12-31
KR101851118B1 (ko) 2018-04-23
RS55084B1 (sr) 2016-12-30
LT2563355T (lt) 2016-09-26
HUE030504T2 (en) 2017-05-29
MX342697B (es) 2016-10-10
HK1179881A1 (en) 2013-10-11
BR112012027623A2 (pt) 2016-08-09
EP2563355A1 (en) 2013-03-06
HK1213872A1 (zh) 2016-07-15
KR20130094212A (ko) 2013-08-23
IL222532A (en) 2017-09-28
JP2013528577A (ja) 2013-07-11
NZ602648A (en) 2014-10-31
PT2563355T (pt) 2016-09-02

Similar Documents

Publication Publication Date Title
US9856207B2 (en) Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects
JP2023027066A (ja) オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
AU2009275665A1 (en) Polymorphic form of rasagiline mesylate
AU2011246707A1 (en) Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers
US20160200716A1 (en) Cobicistat dichlohydrate salt
WO2011095985A2 (en) Rasagiline salts and processes for the preparation thereof
TW202434570A (zh) 嘧啶三唑化合物之固體及共晶體形式
US9266822B2 (en) Solid forms of tacedinaline
HK1213872B (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
HK1179881B (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
US20110263713A1 (en) Polymorphs
WO2012003413A1 (en) Novel solid forms of tacedinaline
JP2026504627A (ja) ピリミジントリアゾール化合物の固体及び共結晶形態
CA2483141A1 (en) Novel trifluoromethylepinephrine compounds and methods of making and using thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140513